2022
Jun 2022

开坦尼 ®(Cadonilimab injection), a first-in-class PD-1/CTLA-4 bi-specific antibody independently developed by the Company, has been granted marketing approval by the NMPA of China for the treatment of recurrent or metastatic cervical cancer (R/M CC) patients that who has progressed on or after platinum-based  chemotherapy.

2021
Aug 2021

The anti PD-1 monoclonal antibody drug 安尼可 ® (Penpulimab monoclonal antibody injection) has been granted marketing approval by the NMPA of China for the treatment of patients with r/r cHL after at least second-line systemic chemotherapy treatment.

2020
Apr 2020

HKEX Listing(Stock Code: 9926)

2019
Aug 2019

We established CTTQ-Akeso

Jun 2019

We formed Sino Biopharm Collaboration to codevelop and co-commercialize penpulimab (AK105)

We obtained the IND approval for a clinical trial of AK112 (PD-1/VEGF) in theUnited States

Mar 2019

We obtained the IND approval for AK104 from the FDA to begin a Phase Ib/II clinical trial in the United States

Jan 2019

The Company was incorporated in the Cayman

Islands as an exempted company with limited liability

2018
May 2018

We initiated a Phase I clinical trial of ebronucimab (AK102) (PCSK9) in China

Mar 2018

We obtained the IND approval for penpulimab (AK105) with respect to cervical cancer and solid tumors from the FDA in the United States

Jan 2018

We initiated a Phase I clinical trial for AK101 (IL-12/IL-23)  in China

2017
Dec 2017

We initiated a Phase I clinical trial for penpulimab (AK105) (PD-1) in  Australia

Oct 2017

We initiated a Phase I clinical trial (with chemotherapy) for AK104 (PD-1/CTLA-4) for the treatment of solid tumors in Australia

2015
Nov 2015

We out-licensed AK107 (CTLA-4) to Merck (code name in Merck is MK1308)

2012
Apr 2012

We initiated the development of innovative ACE Platform and “TETRABODY” technology

Mar 2012

Akeso Biopharma (中山康方生物醫藥有限公司), our principal operating entity, was established in Zhongshan, China